Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Denmark
/
Pharmaceuticals & Biotech
/
Novo Nordisk
NOVO B
Novo Nordisk
Regulatory And Generic Challenges Will Compress Margins But Uplift Pipeline
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 21 Analysts
Published
02 Jun 25
Updated
09 Aug 25
12
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
DKK 340.00
5.7% undervalued
intrinsic discount
09 Aug
DKK 320.50
Loading
1Y
-64.9%
7D
4.8%
Author's Valuation
DKK 340.0
5.7% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
DKK 340.0
5.7% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
357b
2014
2017
2020
2023
2025
2026
2028
Revenue DKK 357.4b
Earnings DKK 120.0b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
8.88%
Pharma revenue growth rate
1.02%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
4.92%
Calculation
DKK 120.03b
Earnings '28
x
14.39x
PE Ratio '28
=
DKK 1.73t
Market Cap '28
DKK 1.73t
Market Cap '28
/
4.40b
No. shares '28
=
DKK 392.59
Share Price '28
DKK 392.59
Share Price '28
Discounted to 2025 @ 4.92% p.a.
=
DKK 339.93
Fair Value '25